Walleye Capital LLC Savara Inc Transaction History

Walleye Capital LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$3.66 - $5.34 $3.38 Million - $4.93 Million	-923,303 Reduced 90.0%	102,536 $413,000
Q1 2024 May 15, 2024	BUY	$4.19 - $5.59 $3.93 Million - $5.24 Million	936,913 Added 1053.59%	1,025,839 $5.11 Million
Q4 2023 Feb 14, 2024	BUY	$3.18 - $4.9 $282,784 - $435,737	88,926 New	88,926 $417,000
Q3 2021 Nov 15, 2021	SELL	$1.18 - $1.64 $22,653 - $31,484	-19,198 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$1.51 - $2.29 $28,988 - $43,963	19,198 New	19,198 $33,000
Q4 2019 Feb 14, 2020	SELL	$0.71 - $4.91 $8,430 - $58,301	-11,874 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$2.16 - $3.2 $25,647 - $37,996	11,874 New	11,874 $31,000

129

158M

67.6K

29.4K

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $369M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.